UY36330A - Compuestos inhibidores de quinasa de unión a tank - Google Patents

Compuestos inhibidores de quinasa de unión a tank

Info

Publication number
UY36330A
UY36330A UY0001036330A UY36330A UY36330A UY 36330 A UY36330 A UY 36330A UY 0001036330 A UY0001036330 A UY 0001036330A UY 36330 A UY36330 A UY 36330A UY 36330 A UY36330 A UY 36330A
Authority
UY
Uruguay
Prior art keywords
quinasa
inhibiting compounds
union
tank
tank union
Prior art date
Application number
UY0001036330A
Other languages
English (en)
Inventor
Du Zhimin
Joshua A Kaplan
John E Knox Jr
Jennifer R Lo
Scott A Mitchell
Naduthambi Devan
Venkataramani Chandrasekar
Wang Peiyuan
William J Watkins
Zhao Zhongdong
Juan A Guerrero
Barton W Phillips
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of UY36330A publication Critical patent/UY36330A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Abstract

Se revelan compuestos que tienen la siguiente fórmula (I) y métodos de su uso y preparación
UY0001036330A 2014-09-26 2015-09-25 Compuestos inhibidores de quinasa de unión a tank UY36330A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462056358P 2014-09-26 2014-09-26
US201562165005P 2015-05-21 2015-05-21

Publications (1)

Publication Number Publication Date
UY36330A true UY36330A (es) 2016-04-29

Family

ID=54251749

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001036330A UY36330A (es) 2014-09-26 2015-09-25 Compuestos inhibidores de quinasa de unión a tank

Country Status (17)

Country Link
US (2) US10040781B2 (es)
EP (2) EP3517536B1 (es)
JP (2) JP6499282B2 (es)
KR (1) KR101949624B1 (es)
CN (1) CN106715419A (es)
AU (1) AU2015320675B2 (es)
BR (1) BR102015024618A2 (es)
CA (1) CA2962578C (es)
EA (1) EA201790395A1 (es)
ES (2) ES2727376T3 (es)
IL (1) IL250875A0 (es)
MX (1) MX2017003930A (es)
NZ (1) NZ729618A (es)
SG (1) SG11201701724VA (es)
TW (1) TW201629046A (es)
UY (1) UY36330A (es)
WO (1) WO2016049211A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201613916A (en) 2014-06-03 2016-04-16 Gilead Sciences Inc TANK-binding kinase inhibitor compounds
EA201790395A1 (ru) 2014-09-26 2017-08-31 Джилид Сайэнс, Инк. Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
CU20180059A7 (es) 2015-12-17 2018-10-04 Gilead Sciences Inc Compuestos inhibidores de la quinasa de unión a tank
AU2017209935B2 (en) 2016-01-22 2021-04-01 Janssen Pharmaceutica Nv New substituted cyanoindoline derivatives as NIK inhibitors
WO2018002219A1 (en) * 2016-06-30 2018-01-04 Janssen Pharmaceutica Nv Cyanoindoline derivatives as nik inhibitors
WO2018002217A1 (en) 2016-06-30 2018-01-04 Janssen Pharmaceutica Nv Heteroaromatic derivatives as nik inhibitors
JP7076741B2 (ja) 2016-12-27 2022-05-30 国立研究開発法人理化学研究所 Ｂｍｐシグナル阻害化合物
JOP20180040A1 (ar) 2017-04-20 2019-01-30 Gilead Sciences Inc مثبطات pd-1/pd-l1
CN109305944B (zh) * 2017-07-28 2022-09-02 深圳睿熙生物科技有限公司 布鲁顿酪氨酸激酶的抑制剂
EP3697773A1 (en) * 2017-10-17 2020-08-26 Merck Patent GmbH PYRIMIDINE TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF
PL3752501T3 (pl) 2018-02-13 2023-08-21 Gilead Sciences, Inc. Inhibitory pd-1/pd-l1
US10899735B2 (en) 2018-04-19 2021-01-26 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
EP3793565B1 (en) 2018-05-14 2022-01-05 Gilead Sciences, Inc. Mcl-1 inhibitors
JP7105359B2 (ja) 2018-07-13 2022-07-22 ギリアード サイエンシーズ， インコーポレイテッド Ｐｄ－１／ｐｄ－ｌ１阻害剤
AU2019366355B2 (en) 2018-10-24 2022-10-13 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
CN111377850B (zh) * 2018-12-31 2022-10-18 艾琪康医药科技（上海）有限公司 一种手性n-取代-3,3-二氟-4-羟基哌啶衍生物及其制备方法
CN109776513A (zh) * 2019-03-18 2019-05-21 福建省医学科学研究院 一类4-苯基-1,3,5-三嗪-2-胺类抗肿瘤化合物及其制备方法
CN110357863B (zh) * 2019-08-27 2023-04-14 药雅科技(上海)有限公司 一种三嗪双芳香环衍生物表皮生长因子抑制剂及其制备方法与用途
CN110862380A (zh) * 2019-10-24 2020-03-06 嘉兴特科罗生物科技有限公司 一种小分子化合物

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
GB0402809D0 (en) 2004-02-09 2004-03-10 Glaxo Group Ltd Chemical compounds
PL3153514T3 (pl) 2004-05-13 2022-01-10 Icos Corporation Chinazolinony jako inhibitory ludzkiej 3-kinazy fosfatydyloinozytolowej delta
RS52010B (en) 2005-06-22 2012-04-30 Plexxikon Inc. DERIVATI PIROLO [2, 3-B] PIRIDINA KAO INHIBITORI PROTEIN KINAZE
CN101495460A (zh) * 2006-05-26 2009-07-29 中外制药株式会社 Hsp90抑制剂
MX2009007302A (es) 2007-01-23 2009-07-15 Palau Pharma Sa Derivados de purina.
KR101737753B1 (ko) 2007-03-12 2017-05-18 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 페닐 아미노 피리미딘 화합물 및 이의 용도
WO2009030890A1 (en) 2007-09-03 2009-03-12 University Court Of The University Of Dundee Pyrimidine compounds for the treatment of cancer, septic shock and/or primary open angle glaucoma
EP2231624A4 (en) * 2007-12-21 2011-07-06 Progenics Pharm Inc TRIAZINE AND CORRESPONDING COMPOUNDS WITH ANTIVIRAL EFFECT, COMPOSITIONS AND METHOD THEREFOR
AR070127A1 (es) 2008-01-11 2010-03-17 Novartis Ag Pirrolo - pirimidinas y pirrolo -piridinas
GB0805477D0 (en) * 2008-03-26 2008-04-30 Univ Nottingham Pyrimidines triazines and their use as pharmaceutical agents
WO2009122180A1 (en) 2008-04-02 2009-10-08 Medical Research Council Pyrimidine derivatives capable of inhibiting one or more kinases
US8450321B2 (en) 2008-12-08 2013-05-28 Gilead Connecticut, Inc. 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor
GB0903759D0 (en) 2009-03-04 2009-04-15 Medical Res Council Compound
DE102009019962A1 (de) 2009-05-05 2010-11-11 Merck Patent Gmbh 3-([1,2,3]Triazol-4-yl)-pyrrolo[2,3-b]pyridinderivate
NZ599826A (en) * 2009-10-12 2014-08-29 Myrexis Inc Amino-pyrimidine compounds as inhibitors of ikk epsilon and/or tbk1
AR078675A1 (es) 2009-10-20 2011-11-23 Cellzome Ltd Derivados de pirazolo[3,4-d]pirimidina inhibidores de jak quinasas, composiciones farmaceuticas que los comprenden, metodo para prepararlos y uso de los mismos para el tratamiento o profilaxis de trastornos inmunologicos, inflamatorios y autoinmunes.
GB201012105D0 (en) * 2010-07-19 2010-09-01 Domainex Ltd Novel pyrimidine compounds
DE102010049877A1 (de) 2010-11-01 2012-05-03 Merck Patent Gmbh 7-((1,2,3)Triazol-4-yl)-pyrrolo(2,3) pyrazinderivate
DE102011008352A1 (de) 2011-01-12 2012-07-12 Merck Patent Gmbh 5-([1,2,3]Triazol-4-yl)-7H-pyrrolo-[2,3-d]pyrimidinderivate
DE102011009961A1 (de) 2011-02-01 2012-08-02 Merck Patent Gmbh 7-Azaindolderivate
KR20140048873A (ko) * 2011-04-12 2014-04-24 알츠하이머즈 인스티튜트 오브 아메리카, 인크. Ｉｋｋ－관련 키나제 엡실론 및 ｔａｎｋ 결합 키나제 1 억제제의 조성물 및 치료학적 용도
ES2699256T3 (es) 2011-05-23 2019-02-08 Merck Patent Gmbh Piridina y derivados de pirazina
SI2714668T1 (sl) 2011-05-23 2017-06-30 Merck Patent Gmbh Tiazolni derivati
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
GB201114051D0 (en) 2011-08-15 2011-09-28 Domainex Ltd Compounds and their uses
EP2562265A1 (en) * 2011-08-22 2013-02-27 Lead Discovery Center GmbH Susceptibility to selective CDK9 inhibitors
DE102011111400A1 (de) 2011-08-23 2013-02-28 Merck Patent Gmbh Bicyclische heteroaromatische Verbindungen
DE102011112978A1 (de) 2011-09-09 2013-03-14 Merck Patent Gmbh Benzonitrilderivate
DE102011119127A1 (de) 2011-11-22 2013-05-23 Merck Patent Gmbh 3-Cyanaryl-1H-pyrrolo[2.3-b]pyridin-Derivate
EP2788000B1 (en) 2011-12-06 2018-05-30 Merck Sharp & Dohme Corp. Pyrrolopyrimidines as janus kinase inhibitors
ES2606637T3 (es) 2012-02-09 2017-03-24 Merck Patent Gmbh Derivados de furo [3,2- b]piridina como inhibidores de TBK1 e IKK
US20130338142A1 (en) 2012-06-14 2013-12-19 Gilead Connecticut, Inc. Imidazopyrazine syk inhibitors
WO2014004863A2 (en) 2012-06-27 2014-01-03 Alzheimer's Institute Of America, Inc. Compounds, compositions, and therapeutic uses thereof
GB201303109D0 (en) 2013-02-21 2013-04-10 Domainex Ltd Novel pyrimidine compounds
TW201444836A (zh) 2013-03-14 2014-12-01 Abbvie Inc 吡咯并［２，３－ｂ］吡啶ｃｄｋ９激酶抑制劑
CN103251600B (zh) 2013-05-27 2015-05-20 中南大学 2-氨基-4-(3′-氰基-4′-吡咯烷基)苯基嘧啶化合物的抗肿瘤应用
US10370664B2 (en) 2013-11-07 2019-08-06 University Of Southern California Use of IKK epsilon inhibitors to activate NFAT and T cell response
EP3444251B1 (en) 2013-12-11 2023-06-07 Biogen MA Inc. Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
WO2015134171A1 (en) 2014-03-06 2015-09-11 Takeda Pharmaceutical Company Limited Heteroarylamide inhibitors of tbk1
TW201613916A (en) 2014-06-03 2016-04-16 Gilead Sciences Inc TANK-binding kinase inhibitor compounds
EA201790395A1 (ru) 2014-09-26 2017-08-31 Джилид Сайэнс, Инк. Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
WO2016057338A1 (en) 2014-10-06 2016-04-14 Takeda Pharmaceutical Company Limited Heteroarylamide inhibitors of tbk1
MX2017015357A (es) 2015-06-29 2018-03-16 Merck Patent Gmbh Compuestos inhibidores de serina/treonina-proteina cinasa (tbk)/inhibidor de cinasa de factor nuclear kappa-b subunidad epsilon (ikk-epsilon) y usos de los mismos.
CU20180059A7 (es) 2015-12-17 2018-10-04 Gilead Sciences Inc Compuestos inhibidores de la quinasa de unión a tank

Also Published As

Publication number Publication date
WO2016049211A1 (en) 2016-03-31
NZ729618A (en) 2018-07-27
SG11201701724VA (en) 2017-04-27
AU2015320675A1 (en) 2017-03-23
MX2017003930A (es) 2017-06-30
CA2962578A1 (en) 2016-03-31
KR101949624B1 (ko) 2019-02-18
CN106715419A (zh) 2017-05-24
EA201790395A1 (ru) 2017-08-31
KR20170049609A (ko) 2017-05-10
US20180370955A1 (en) 2018-12-27
IL250875A0 (en) 2017-04-30
BR102015024618A2 (pt) 2016-08-23
CA2962578C (en) 2019-01-08
JP2017529373A (ja) 2017-10-05
EP3197884B1 (en) 2019-03-06
AU2015320675B2 (en) 2018-10-18
EP3517536A1 (en) 2019-07-31
EP3197884A1 (en) 2017-08-02
US20160096827A1 (en) 2016-04-07
EP3517536B1 (en) 2021-05-05
TW201629046A (zh) 2016-08-16
JP2018158942A (ja) 2018-10-11
US10040781B2 (en) 2018-08-07
JP6499282B2 (ja) 2019-04-10
ES2881195T3 (es) 2021-11-29
ES2727376T3 (es) 2019-10-15
US10253019B2 (en) 2019-04-09

Similar Documents

Publication Publication Date Title
UY36330A (es) Compuestos inhibidores de quinasa de unión a tank
CR20180320A (es) Compuestos inhibidores de la quinasa de union a tank
ECSP17029371A (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
NI201700034A (es) Indazoles sustituidos con benzilo como inhibidores de bub1.
MA40058A (fr) Composés inhibiteurs de kinases se liant à tank
CR20160419A (es) Nuevos compuestos biciclicos
MA40943A (fr) Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
ES2796903T8 (es) Procedimiento de uso de inmunoconjugados anti-CD79b
MA40940A (fr) Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
CR20140501A (es) Nuevos diazaespirocicloalcanos y azaespirocicloalcanos
BR112016022658A2 (pt) anticorpos anti-ox40 e métodos de uso
MX2017008442A (es) Uso de picolinamidas como fungicidas.
BR112017005266A2 (pt) inibidores de mk2 e uso dos mesmos
ECSP17015977A (es) Terapia de combinacion
DK3116475T3 (da) Dopa-decarboxylasehæmmersammensætninger
BR112016026046A2 (pt) Uso de compostos de tienotriazolodiazepina
BR112016020181A2 (pt) Composições de ácido lipoico éster colina e métodos de uso.
DOP2018000066A (es) Compuestos útiles para inhibir ror-gamma-t
CL2017000587A1 (es) Derivados de tetrahidroquinolina como inhibidores de bromodominio
BR112017002090A2 (pt) formulação de fator viii
BR112017007753A2 (pt) uso de uma composição cosmética que compreende ácido 10-hidroxiesteárico.
ITUA20161994A1 (it) Uso degli inibitori ddx3 come agenti anti-iperproliferativi
BR112016028941A2 (pt) uso de antiespumantes como aditivos antideriva".
MX2022010854A (es) Peptidos toxicos activados artificialmente.
CR20150352A (es) Nuevas composiciones antifúngicidas

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20220705